Key facts
- PAM2L Biotechnologies’s last known valuation is $88.8M (Jan 2023).
- It has raised $19.1M; the latest was Early Stage VC in Nov 2025.
- Notable investors include Co-Stone Capital, 5Y Capital, Yunqi Partners, Shenzhen Angel Investment Guiding Fund, Guangzhou Guangyao Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for PAM2L Biotechnologies
- ·The full record, as it builds
Funding rounds
No funding rounds for PAM2L Biotechnologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PAM2L Biotechnologies
Developer of biomaterial innovation and application intended for the synthetic biology sector. The company mainly focuses on the development of protein and polysaccharide raw materials, thereby enabling customers to access safe, efficient, and sustainable biomaterial solutions.
- Sector
- Materials and Resources
- HQ
- Shenzhen, China
- Founded
- 2021
- Website
- pam2l.com/
- Ownership
- Privately Held (backing)
PAM2L Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PAM2L Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PAM2L Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.